The management of abnormalities of hemostasis in acute liver failure

Seminars in Liver Disease

Volumn 16, Issue 4, 1996, Pages 403-414

  Pereira, Stephen P ^a   Langley, Peter G ^a   Williams, Roger ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

acute liver failure; coagulation factors; disseminated intravascular coagulation; fibrinolysis; platelets

Indexed keywords

AMINOCAPROIC ACID; ANTITHROMBIN III; APROTININ; HEPARIN; PROTEIN C; TRANEXAMIC ACID; VITAMIN K GROUP;

BLEEDING; BLOOD TRANSFUSION; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIVER FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; TREATMENT PLANNING;

EID: 0030451520     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007253     Document Type: Review

References (193)

1. Roberts HR, Cederbaum AI: The liver and blood coagulation: physiology and pathology. Gastroenterology 63:297-320, 1972.
2. Fiore L, Levine J, Deykin D: Alterations of hemostasis in patients with liver disease. In: Zakim D, Boyer TD (eds): Hepatology. A textbook of liver disease, Philadelphia, WB Saunders, 1990, 546-71.
3. Mackie IJ: The biology of haemostasis and thrombosis. In: Weatherall DJ, Ledingham JGG. Warrell DA (eds): Oxford Textbook of Medicine, 3rd Edition. Oxford, Oxford University Press, 1996, 3613-27.
4. Canalese J, Gove CD, Gimson AE, et al: Reticuloendothelial system and hepatocyte function in fulminant hepatic failure. Gut 23:265-9, 1982.
5. Kelly DA, Tuddenham EG: Haemostatic problems in liver disease. Gut 27:339-49, 1986.
6. O'Grady JG, Langley PG, Isola LM, et al: Coagulopathy of fulminant liver disease. Sem Liver Dis 6:159-63, 1986.
7. Páramo JA, Rocha E: Hemostasis in advanced liver disease. Sem Thromb Hemost 19:184-90, 1993.
8. Gentry PA: The mammalian blood platelet: its role in haemostasis, inflammation and tissue repair. J Comp Path 107:243-70, 1992.
9. Clark R, Rake MO, Flute PT, Williams R: Coagulation abnormalities in acute liver failure; pathogenetic and therapeutic implications. Scand J Gastroenterol 8(suppl 19):63-70, 1973.
10. Weston MJ, Langley PG, Rubin MH, et al: Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 18:897-902. 1977.
11. Gimson AE, Braude S, Mellon PJ, et al: Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 2:681-3, 1982.
12. Gimson AE. O'Grady J, Ede RJ. et al: Late onset hepatic failure: clinical, serological and histological features. Hepatology 6:288-94. 1986.
13. Rubin MH, Weston MJ, Bullock G, et al: Abnormal platelet function and ultrastructure in fulminant hepatic failure. Q J Med 46:339-52, 1977.
14. Rubin MH, Weston MJ, Langley PG, et al: Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 24:197-202, 1979.
15. Siemensma NP. Bathal PS. Penington DG: The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med 86:817-33, 1975.
16. Kaushansky K, Lok S, Holly RD, et al: Promotion of megaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568-71, 1994.
17. Wendling F. Maraskovsky E, Debill N, et al: C-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 369:571-4, 1994.
18. de Sauvage FJ, Hass PE, Spencer SD, et al: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533-8, 1994.
19. Lok S. Kaushansky K, Holly RD, et al: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565-8, 1994.
20. Graber D, Giuliani D, Leevy CM, Morse B: Platelet associated IgG in hepatitis and cirrhosis. J Clin Immunol 4:108-11, 1984.
21. Puram V, Giuliani D, Morse B: Circulating immune complexes and platelet IgG in various diseases. Clin Exp Immunol 58:672-6, 1984.
22. Schmidt KG, Rasmussen J, Bekker C, Madsen PE: Kinetics and in vivo distribution of 111-In-labeled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol 34:39-46, 1985.
23. Kajiwara E, Akagi K, Azuma K, et al: Evidence for an immunological pathogenesis of thrombocytopenia in chronic liver disease. Am J Gastroenterol 962-6, 1995.
24. Guillin MC, Menache D, Barge J, et al: Hemostasis disorders during severe viral hepatitis: clinical, anatomical and biological study. Ann Med Int 122:605-12, 1971.
25. Bertaglia E, Belmonte P, Vertolli U. et al: Bleeding in cirrhotic patients: a precipitating factor due to intravascular coagulation or to hepatic failure? Haemostasis 13:328-34, 1983.
26. Violi F, Leo R, Vezza E, et al: Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. J Hepatol 20:531-6, 1994.
27. Langley PG, Hughes RD, Williams R: Platelet adhesiveness to glass beads in liver disease. Acta Haematol 67:124-7, 1982.
28. Langley PG, Keays R, Hughes RD, et al: Antithrombin HI supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology 14:251-6, 1991.
29. Langley PG, Hughes RD, Williams R: Increased factor VIII complex in fulminant hepatic failure. Thromb Haem 54:693-6, 1985.
30. Langley PG, Gove CD, Williams R: Altered platelet lipids and their effect on platelet function in fulminant hepatic failure. In: Kleinberger G, Ferenci P, Riederer P, Thaler H (eds): Advances in Hepatic Encephalopathy and Urea Cycle Diseases. Basel, S. Karger, I984, 706-10.
31. Kaplan KL, Owen J: Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57:199-202, 1981.
32. Hughes RD, Lane DA, Ireland H, et al: Fibrinogen derivatives and platelet activation products in acute and chronic liver disease. Clin Sci 68:701-7, 1985.
33. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: initiation, maintenance and regulation. Biochemistry 30:10363-70, 1991.
34. Hambley H: Coagulation (I) - factors and pathways. Care Critic III 11:160-5, 1995.
35. Broze GJ: Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Trends Cardiovasc Med 2:72-7, 1992.
36. Broze GJ: Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med 46:103-12, 1995.
37. Takahashi H, Satoh N, Wada K, et al: Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 46:333-7, 1994.
38. Mannucci PM: Mechanisms, markers and management of coagulation activation. Br Med Bull 50:851-70, 1994.
39. Rake MO, Flute PT, Pannell G, Williams R: Intravascular coagulation in acute hepatic necrosis. Lancet 2:533-7, 1970
40. Gazzard BG, Clark R, Borirakchanyavat V, Williams R: A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis. Gut 15:89-93. 1974.
41. Gazzard BG, Henderson JM, Williams R: Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 16:617-20. 1975.
42. Gazzard BG, Henderson JM. Williams R: Factor VII levels as a guide to prognosis in fulminant hepatic failure. Gut 17:489-91, 1976.
43. O'Grady JG, Alexander GJM, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97:439-45, 1989.
44. Harrison PM, O'Grady JG, Keays RT, et al: Serial prothrombin time as prognostic indicator in paracetamol-induced fulminant hepatic failure. Br Med J 301:964-6, 1990.
45. O'Grady JG, Schalm SW, Williams R: Acute liver failure: redefining the syndromes. Lancet 342:273-5, 1993.
46. Bemuau J. Goudeau A, Poynard T, et al: Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 6:648-51, 1986.
47. Pereira LM, Langley PG, IIayllar KM, et al: Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic factors. Gut 33:98-102, 1992.
48. Bismuth H, Samuel D. Castaing D, et al: Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 222:109-19, 1995.
49. Boks AL, Brommer EJP, Schalm SW, Van Vliet HH: Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 6:79-86, 1986.
50. de Toledo CF, Borges DR: Plasma kallikrein clearance by the liver of acetaminophen-intoxicated rats. Life Sci 52:1451-9, 1993.
51. Segal HC. Hunt BJ. Cottam S, et al: Changes in the contact system during orthotopic liver transplantation with and without aprotinin. Transplantation 59:366-70, 1995.
52. Meili EO, Straub PW: Elevation of factor VIII in acute fatal liver necrosis. Thromb Diath Haemorrh 24:161-74, 1970.
53. Owen CA Jr, Rettke SR, Cole TL, et al: Hemostatic evaluation of patients undergoing liver transplantation. Mayo Clin Proc 62:761-72, 1987.
54. Rueff B, Benhamou JP: Acute hepatic necrosis and fulminant hepatic failure. Gut 14:805-15, 1973.
55. Christen Y, Minazio P. de Moerloose P: Monitoring of haemostatic parameters in five cases of Amanita phalloides poisoning Blood Coag Fibrinol 4:627-30, 1993.
56. Gazzard BG, Clark R, Flute PT, Williams R: Factor VIII levels during the course of acute hepatitis in a haemophiliac. J Clin Pathol 28:972-74. 1975.
57. Lewis JH, Bontempo FA, Awad SA. et al: Liver transplantation: intraoperative changes in coagulation factors in 100 first transplants. Hepatology 9:710-14, 1989.
58. Kelly DA. O'Brien FJ. Hutton RA. et al: The effect of liver disease on factors V, VIII and protein C. Br J Haematol 61:541-8, 1985.
59. Kaufman RJ: Biological regulation of factor VIII activity. Annu Rev Med 43:325-39, 1992.
60. Fay PJ: Factor VIII structure and function. Thrombos Haemost 70:63-7. 1993.
61. Blann AD, Taberner DA: A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 90:244-8, 1995.
62. Knittel T, Neubauer K, Armbrust T, Ramadori G: Expression of von Willebrand factor in normal and diseased rat livers and in cultivated liver cells. Hepatology 21:470-6, 1995.
63. Wion KL, Kelly D, Summerfield JA. et al: Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317:726-9, 1985.
64. Shimomura T, Kondo J, Ochiai M, et al: Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 268:22972-32, 1993.
65. Hoffman AL. Rosen HR, Ljubimova JU, et al: Hepatic regeneration: current concepts and clinical implications, Sem Liver Dis 14:190-210, 1994.
66. Pernambuco JR, Hughes RD, Langley PG, et al: Hepatocyte growth factor and plasminogen activation in fulminant hepatic failure. Blood Coag Fibrinol 5:511-15, 1994.
67. Tsubouchi H, Hirono S, Gohda E, et al: Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology 9:875-81, 1989.
68. Shiota G, Okano J, Umeki K, et al: Serum hepatocyte growth factor in acute hepatic failure in comparison with acute hepatitis. Res Commun Mol Pathol Pharmacol 85:157-62, 1994.
69. Kalafatis M. Swords NA, Rand MD, Mann KG: Membranedependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1227:113-29, 1994.
70. Shearer MJ: Vitamin K metabolism and nutriture. Blood Rev 6:92-104, 1992.
71. Shearer MJ: Vitamin K. Lancet 345:229-34, 1995.
72. Conly JM, Stein K: Quantitative and qualitative measurements of K vitamins in human intestinal contents. Am J Gastroenterol 87:311-16, 1992.
73. 2) by intestinal bacteria and their role in maintaining coagulation homeostasis. Progr Food Nutr Sci 16:307-43, 1992.
74. Shearer MJ, McCarthy PT, Crampton OE, Mattock MB: The assessment of human vitamin K status from tissue measurements. In: Suttie JW (ed): Current advances in Vitamin K research. New York, Elsevier. 1988, 437-52.
75. 1 concentrations. J Clin Pathol 6: 39:1245-9. 1986.
76. 1 levels. Br J Haematol 68:63-6, 1988.
77. Shearer MJ, Bechtold H, Andrassy K, et al: Mechanism of cephalosponn-induced hypoprothrombinemia: relation to cephalosponn side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 28:88-95, 1988.
78. Shevchuk YM, Conly JM: Antibiotic-associated hypoprothrombinaemia. Rev Infect Dis 12:1109-26, 1990.
79. Mehta R, Reilly JJ, Olson RE: Vitamin K therapy in severe liver disease. J Parenter Enterai Nutr 15:350-3, 1991.
80. Rosenberg RD, Damus PS: The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248:6490-6505, 1973.
81. Marcum JA. Rosenberg RD: Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 126:365-72, 1985.
82. Marcum JA. Rosenberg RD: Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 23:1730-7, 1984.
83. Kemkes-Matthes B, Bleyl H, Matthes KJ: Coagulation activation in liver diseases. Thromb Res 64:253-61. 1991.
84. Ducken F: Behaviour of antithrombin III in liver disease. Scand J Gastroenterol 8(suppl 19):109-12. 1973.
85. Sette H, Hughes RD, Langley PG. et al: Heparin response and clearance in acute and chronic liver disease. Thromb Haemost 54:591-4, 1985.
86. Langley PG, Forbes A. Hughes RD, Williams R: Thrombinantithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome. Eur J Clin Invest 20:627-31, 1990.
87. Langley PG, Williams R: Physiological inhibitors of coagulation in fulminant hepatic failure. Blood Coag Fibrinol 3:243-7, 1992.
88. Gabriel DA; The use of antithrombin III in the treatment of disseminated intravascular coagulation. Sem Hematol 31:60-4, 1994.
89. Ceustermans R. Hoylaerts M, De Mol M, Collen D: Preparation, characterization, and turnover properties of heparin-antithrombin III complexes stabilized by covalent bonds. J Biol Chem 257:3401-8, 1982.
90. Walker FJ: Protein C deficiency in liver disease. Annals Clin Lab Sci 20:106-12, 1990.
91. Langley PG, Williams R: The effect of fulminant hepatic failure on protein C antigen and activity. Thromb Haem 59:316-18, 1988.
92. D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC: Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascuiar coagulation. J Clin Invest 81:1445-54, 1988.
93. Takahashi H, Tatewaki W. Wada K, Shibata A: Plasma protein S in disseminated intravascular coagulation, liver disease, collagen disease, diabetes mellitus, and under oral anticoagulant therapy. Clin Chim Acta 182:195-208, 1989.
94. Bell H, Ødegaard OR, Andersson T, Raknerud N: Protein C in patients with alcoholic cirrhosis and other liver diseases. J Hepatol 14:163-7, 1992.
95. Izumi S, Hughes RD, Langley PG, et al: Extent of the acute phase response in fulminant hepatic failure. Gut 35:982-6, 1994.
96. 1-antitrypsin complex in fulminant hepatic failure: relationship to bacterial infection and activation of coagulation. Clin Chim Acta 200-211-19, 1991.
97. Sandset PM, Abildgaard U, Larsen ML: Heparm induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50:803-13, 1988.
98. Novotny WF, Girard TG, Miletich JP. Broze GJ Jr: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor. Blood 72:2020-5, 1988.
99. Novotny WF. Brown SG. Miletich JP, et al: Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78:387-93. 1991.
100. Sandset PM, Abildgaard U: Extrinsic pathway inhibitor - the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 21:219-39. 1991.
101. Novotny WF: Tissue factor pathway inhibitor. Sem Thromb Hemost 20:101-8, 1994.
102. Sandset PM, Warn-Cramer BJ, Rao LV, et al: Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88:708-12. 1991.
103. Sandset PM, Warn-Cramer BJ, Maki SL. Rapaport SI: Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Schwartzman reaction. Blood 78:1496-1502, 1991.
104. Bajaj MS. Rana SV. Wysolmerski RB, Bajaj SP: Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 79:1874-8. 1987
105. Warr TA, Rao LV. Rapaport SI: Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 74:994-8. 1989.
106. Day KC, Hoffman LC. Palmier MO. et al: Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 76:1538-45. 1990.
107. Creasey AA. Chang AC, Feigen L. et al: Tissue factor pathway inhibitor reduces mortality from Eschericia coli septic shock. J Clin Invest 91:2850-6. 1993.
108. Lasierra J, Aza MJ, Vilades E, et al: Tissue plasminogen activator and plasminogen activator in patients with liver cirrhosis. Fibrinolysis 5:117-20, 1991.
109. Edelberg JM, Reilly CF. Pizzo SV: The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-I: the effects of fibrinogen. heparin, vitronectin, and lipoprotein(a). J Biol Chem 266:7488-93, 1991.
110. 2-plasmin inhibitor-plasmin complex and FDP-D-Dimer in fulminant hepatic failure. Thromb Res 53:253-60, 1989.
111. Hillenbrand P. Parbhoo SP, Jedrychowski A, Sherlock S: Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 15:83-8, 1974.
112. 2-plasmin inhibitor levels in liver disease. Clin Chim Acta 84:88-105, 1978.
113. Pernambuco JR. Langley PG. Hughes RD, et al: Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 18:1350-6, 1993.
114. Pernambuco JR. Langley PG, Hughes RD, et al: Fibrinolytic abnormalities following liver transplantation in patients with fulminant hepatic failure. Eur J Gastroenterol Hepatol 7:155-9, 1995.
115. 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome. Behring Inst Mitt 79:87-103. 1986.
116. Tada K, Akamatsu K, Konno T, Ohta Y: Importance of measuring plasma thrombin-antithrombin III complex levels when using antithrombin III concentrate therapy in fulminant hepatic failure. Scand J Gastroenterol 26-1188-92, 1991
117. Leiper K, Croll A, Booth NA. et al: Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. J Clin Pathol 47:214-17, 1994.
118. Clark RD. Gazzard BG, Lewis ML, et al: Fibrinogen metabolism in acute hepatitis and active chronic hepatitis. Br J Haematol 30:95-102, 1975.
119. Francis RB, Feinstein DI: Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 14:460-5, 1984.
120. Takahashi H, Tatewaki W. Wada K, et al: Fibrinolysis and fibrinogenolysis in liver disease. Am J Hematol 34:241-5, 1990.
121. Lane DA. Scully MF. Thomas DP. et al: Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol 35:301-8, 1977.
122. Palascak JE, Martinez J: Dysfibrinogenemia associated with liver disease. J Clin Invest 60:89-95, 1977.
123. Francis JL. Armstrong DJ: Fibrinogen-bound sialic acid levels in the dysfibnnogenaemia of liver disease. Haemostasis 11:215-22. 1982.
124. Martinez J. MacDonald KA. Palascak JE: The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 61:1196-1202, 1983.
125. Martinez J, Barsigian C: Carbohydrate abnormalities of N-linked plasma glycoproteins in liver disease. Lab Invest 37:240-57, 1987.
126. Green G, Thompson JM, Dyraock IW, Poller L: Abnormal fibrin polymerization in liver disease. Br J Hematol 34:427-39, 1976.
127. Dittman W A, Majerus PW: Structure and function of thrombomodulin: a natural anticoagulant. Blood 75:329-36. 1990.
128. Ye J, Esmon NL, Esmon CT, Johnson AE: The active site of thrombin is altered upon binding to thrombomodulin. Two distinct structural changes are detected by fluorescence, but only one correlates with protein C activation. J Biol Chem 266:23016-21, 1991.
129. Takano O, Kimura S, Ohdama S, Aoki N: Plasma thrombomodulin in health and diseases. Blood 76:2024-9, 1990.
130. Bik RL: Disseminated intravascular coagulation. Hematol Oncol Clin North Am 6:1259-85, 1992.
131. Bloom AL: Intravascular coagulation and the liver. Br J Haematol 30:l-7, 1975.
132. Coleman M, Finlayson N, Bettigole RE, et ai: Fibrinogen survival in cirrhosis: improvement by "low dose" heparin. Ann Intern Med 83:79-81, 1975.
133. Van Wersch JW, Russel MG, Lustermans FA: The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis. Eur J Clin Chem Clin Biochem 30:275-9, 1992.
134. de Maat MP, Nieuwenhuizen W. Knot EA: Measuring plasma fibrinogen levels in patients with liver cirrhosis: the occurrence of proteolytic fibrin(ogen) degradation products and their influence on several fibrinogen assays. Thromb Res 78:353-62, 1995.
135. Violi F, Ferro D, Basili S, et al: Association between lowgrade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 109:531-9, 1995.
136. Singh R, Singh MM, Hazra DK, et al: A study of disseminated intravascular coagulopathy in hepatic coma complicating acute viral hepatitis. Angiology 34:470-9, 1983.
137. Rake MO, Flute PT, Shilkin KB, et al: Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet 2:1215-18, 1971.
138. Cano RI, Delman MR, Pitchumoni CS, et al: Acute fatty liver of pregnancy: complication by disseminated intravascular coagulation. JAMA 231:159-61. 1975.
139. Preston FE: Haemorrhagic diathesis and control. In: Williams R, Hughes RD (eds): Acute Live Failure: Improved Understanding and Better Therapy. London, Miter Press, 1991, pp 36-9.
140. Nossel HL, Yudelman I, Canfield RE, et al: Measurement of fibrinopeptide A in human blood. J Clin Invest 54:43-53, 1974.
141. Nossel HL, Wassner J, Kaplan KL, et al: Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. J Clin Invest 64:1371-8. 1979.
142. Nolan JP: Intestinal endotoxins as mediators of hepatic injury - an idea whose time has come again. Hepatology 10:887-91, 1989.
143. Hirata K, Ogata I, Ohta Y, Fujiwara K: Hepatic sinusoidal cell destruction in the development of intravascular coagulation in acute liver failure of rats. J Pathol 158:157-65, 1989.
144. Bredbacka S, Blombäck M, Wiman B: Soluble fibrin: a predictor for the development and outcome of multiple organ failure. Am J Hematol 46:289-94, 1994.
145. Hewett JA, Roth RA: The coagulation system, but not circulating fibrinogen. contributes to liver injury in rats exposed to lipopolysaccharide from gram-negative bacteria. J Pharmacol Exp Ther 272:53-62, 1995.
146. Neubauer K, Knittel T, Armbrust T, Ramadon G: Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury. Gastroenterology 108:1124-35, 1995.
147. Pearson ID: Endolhelial cell function and thrombosis. Baillieres Clin Haematol 7:441-52, 1994.
148. Muto Y, Nouri-Aria KT, Meager A, et al: Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2:72-4. 1988.
149. Esmon CT: Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Clin Haematol 7:453-68, 1994.
150. Jordan RE, Kilpatrick J. Nelson RM: Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 237:777-9, 1987.
151. Pratt CW, Tobin RB, Church FC: Interaction of heparin cofactor II with neutrophil elastase and cathespin G. J Biol Chem 265:6092-7, 1990.
152. 1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 257:9849-54, 1982.
153. Higuchi DA. Wun T-C, Liken KM, Broze GJ Jr: The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 79:1712-19. 1992.
154. MacDougall BR, Williams R: H2 receptor antagonist in the prevention of acute upper gastrointestinal hemorrhage in fulminant hepatic failure: a controlled trial. Gastroenterology 74:464-5, 1978.
155. McCarthy DM: Sucralfate. N Engl J Med 325:1017-25, 1991.
156. Williams R, Gimson AE: Intensive liver care and management of acute hepatic failure. Dig Dis Sci 36:820-6, 1991.
157. Williams R: New directions in acute liver failure. J Roy Coll Physic 28:552-9, 1994.
158. Rintels PB, Kenney RM, Crowley JP: Therapeutic support of the patient with thrombocytopenia. Hematol Oncol Clin North Am 8:1131-57, 1994.
159. Mannucci PM: Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 72:1449-55, 1988.
160. Agnelli G, Berrettini M, De Cunto M, Nenci GG: Desmopressininduced improvement of abnormal coagulation in chronic liver disease. Lancet 1:645, 1983.
161. Burroughs AK, Matthews K, Qadiri M, et al: Desmopressin and bleeding time in patients with cirrhosis. Br Med J 291:1377-81, 1985
162. Soslau G, Schwanz AB, Putatunda B, et al: Desmopressin-induced improvement in bleeding times in chrome renal failure patients correlates with platelet serotonin uptake and ATP release. Am J Med Sci 300:372-9. 1990.
163. Munoz SJ, Bailas SK, Moritz MJ, et al: Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis. Transplant Proc 21:3535-6, 1989.
164. Kondrup J, Almdal T, Vilstrup H, Tygstrup N: High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs 15:669-76, 1992.
165. Goldfarb G, Lebrec D: Percutaneous cannulanon of the internal jugular vein in patients with coagulopathies: an experience based on 1,000 attempts. Anesthesiology 56:321-3, 1982.
166. Foster PF, Moore LR, Sankary HN, et al: Central venous catheterization in patients with coagulopathy. Arch Surg 127:273-5, 1992.
167. Humphries JE: Transfusion therapy in acquired coagulopathies. Hematol Oncol Clin North Am 8:1181-1201, 1994.
168. Caraceni P, Van Thiel DH: Acute liver failure. Lancet 345:163-9, 1995.
169. Gazzard GB. Lewis ML. Ash G, et al: Coagulation factor concentrate in the treatment of the haemorrhagic diathesis of fulminant hepatic failure. Gut 15:993-8, 1974.
170. Anderson BJ, Keeley SR, Johnson ND: Prothrombinex-induced thrombosis and its management with regional plasminogen activator in hepatic failure. Med J Aust 153:352. 355-6, 1990.
171. Saibara T, Maeda T, Onishi S, Hamamoto Y: Plasma exchange and the arterial blood ketone body ratio in patients with acute hepatic failure. J Hepatol 20:617-22, 1994.
172. Egbring R, Seitz R: Improved prognosis of fulminant hepatic failure (FHF) after plasma derivative replacement therapy. Enhanced proteolysis of hemostatic proteins confirmed by proteinase-inhibitor complexes determination. Z Gastroenterol 28:104-9, 1990.
173. Fujiwara K, Ogata I, Ohta Y, et al: Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III. Gut 29:1103-8, 1988.
174. Emerson TE, Fournel MA, Leach WJ, Redens TB: Protection against disseminated intravascular coagulation and death by antithrombin III in the Escherichia coli endotoxemic rat. Circ Shock 21:1-13, 1987.
175. Hauptmaa JG, Hassouna HI, Bell TG, et al: Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation. Circ Shock 25.111-22. 1988.
176. Dickneite G, Pâques E-P: Reduction of mortality with antithrombin III in septicemie rats: a study of Klebsiella penumoniae induced sepsis. Thromb Haemost 69:98-102, 1993.
177. Emerson TE: Antithrombin III replacement in animal models of acquired antithrombin III deficiency. Blood Coag Fibrinol 5(suppl 1):S37-S45, 1994.
178. Laursen B, Mortensen JZ, Frost L, Hansen KB: Disseminated intravascular coagulation in hepatic failure treated with antithrombin III. Thromb Res 22:701-4, 1981.
179. Hellgren M. Hägnevik K, Robbe H, et al: Severe acquired antithrombin III deficiency in relation to hepatic and renal insufficiency and intrauterine fetal death in late pregnancy. Gynecol Obstet Invest 16:107-18, 1983.
180. Fujiwara K, Okita K, Akamatsu K, et al: Antithrombin ni concentrate in the treatment of fulminant hepatic failure. Gastroenterol Jap 23:423-7, 1988.
181. Lechner K, Kyrie PA: Antithrombin III concentrates-are they clinically useful? Thromb Haemost 73:340-8, 1995.
182. Langley PG. Hughes RD, Forbes A, et al: Controlled trial of an-tithrombin III supplementation in fulminant hepatic failure. J Hepatol 17:326-31. 1993.
183. Fricke W. Ailing D, Kimball J. et al: Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion 31:345-8, 1991.
184. Garewal HS, Durie BG: Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand J Haematol 35:497-500, 1985.
185. Bechstein WO, Riess H. Blumhardt G, et al: Aprotinin in orthotopic liver transplantation. Sem Thromb Hemost 19:262-7, 1993.
186. Scudamore CH, Randall TE, Jewesson PJ, et al: Aprotinin reduces the need for blood products during liver transplantation. Am J Surg 169, 546-9, 1995.
187. Hull RD, Raskob GE, Pineo GF, et al: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326:975-82, 1992.
188. Salzman EW: Low molecular weight hepann and other new antithrombotic drugs. N Engl J Med 326:1017-19, 1992.
189. Friedel HA, Balfour JA: Tinzaparin: a review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 48:638-60, 1994.
190. Gimson AE, Langley PG. Hughes RD, et al: Prostacyclin to prevent activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet 1:173-5, 1980.
191. Woods HF, Weston MJ, Bunting S. et al: Prostacyclin eliminates the thrombocytopenia associated with charcoal hemoperfusion and minimizes heparin and fibrinogen consumption. Artif Organs 4:176-9, 1980.
192. Bihari D, Smithies M, Gimson A, Tinker J: The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 317:397-403, 1987.
193. Wendon JA, Harrison PM, Keays R, et al: Arterial-venous pH differences and tissue hypoxia in patients with fulminant hepatic failure. Crit Care Med 19:1362-4, 1991.